Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2002-02-27
2008-03-25
Saoud, Christine J. (Department: 1646)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C530S326000, C530S327000, C530S402000, C530S323000, C530S300000, C435S007100, C424S193100, C436S547000
Reexamination Certificate
active
07348010
ABSTRACT:
The present invention relates to peptides of the extracellular domain of a HER-2
eu protein, conjugates comprising said peptides linked to an immunogenic carrier, compositions thereof, nucleic acid molecules, vectors and transformed or transfected host cells comprising said nucleic acid molecules encoding said peptides or conjugates, and methods for producing the disclosed peptides, conjugates and compositions. The present invention also relates to diagnostic methods of detecting cancerous conditions associated with HER-2
eu or monitoring the effectiveness of treatment against cancerous conditions associated with HER-2
eu. The present invention also relates to methods of eliciting or enhancing an immune response to HER-2
eu in a subject in need thereof.
REFERENCES:
patent: 5772997 (1998-06-01), Hudziak et al.
patent: 5801005 (1998-09-01), Cheever et al.
patent: 5869445 (1999-02-01), Cheever et al.
patent: 6610297 (2003-08-01), Kricek et al.
patent: 7060284 (2006-06-01), Kaumaya et al.
patent: 117165 (1993-05-01), None
patent: WO 96/18409 (1996-06-01), None
patent: WO 98/17797 (1998-04-01), None
patent: WO 9817797 (1998-04-01), None
patent: WO 99/33969 (1999-08-01), None
patent: WO 99/57981 (1999-11-01), None
patent: WO 01/08636 (2001-02-01), None
Woodbine , Abstract P442, “Biological Effects of Peptide Antibodies Raised to HER-2
eu. Implications for Therapy of Human Breast Cancer” by Woodbine, et al., The 1997 American Peptide Symposium, Jun. 14-19, 1997, Nashville, Tennessee.
Perosa et al. (Ann. N.Y. Acad. Sci. 1051: 672-683, 2005.
Poczatek et al (1999) “Ep-Cam Levels in Prostatic Adenocarcinoma and Prostatic Intraepithelial Neoplasia”The Journal of Urology, vol. 162, pp. 1462-1466.
Punt (1998) “New Drugs in the Treatment of Colorectal Carcinoma”Cancer, vol. 83, No. 4, pp. 679-689.
Riethmuller et al. (1994) “Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma”The Lancet, vol. 343, pp. 1177-1183.
Samonigg et al. (1999) “A Double-Blind Randomized-Phase II Trial Comparing Immunization with Antiidiotype Goat Antibody Vaccine SVC 106 Versus Upspecific Goat Antibodies in Patients with Metastatic Colorectal Cancer”Journal of Immunotherapy, vol. 22(6): pp. 481-488.
Stoute et al. (1995) “Induction of Humoral Immune Response againstPlasmodium falciparumSporozoites by Immunication with a Synthetic Peptide Mimotope Whose Sequence Was Derived from Screening a Filamentous Phage Epitope Library”Infection and Immunity, vol. 63, No. 3 pp. 934-939.
Treon et al. (2000) “Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens”Annals of OncologyII Supp S107-S111.
Turpen et al. (1995) “Malarial Epitopes Expressed on the Surface of Recombinant Tobacco Mosaic Virus”Bio/Technologyvol. 13, pp. 53-57.
Zwick, et al. (1998) “Phage-displayed peptide libraries”Current Opinion in Biotechnology, vol. 9: pp. 427-436.
Baselga et al. (1988) “Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Pacilitaxel and Doxorubin against HER2
eu Overexpressing Human Breast Cancer Xenografts”, Cancer Research 58: 2825-2831.
Baselga, et al. (2000) “Phase I Studies of Anti-Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin”, Journal of Clinical Oncology, vol. 18, No. 4, pp. 904-914.
Behr et al. (1999) “Low-versus High-Dose Radioimmunotherapy with Humanized Anti-CD22 or Chimerica Anti-CD20 Antibodies in a Broad Spectrum of B Cell-associated Malignancies”, Clinical Cancer Research vol. 5, 3304s-3314s.
Braun et al. (1999) “Monoclonal Antibody Therapy with Edrecolomab in Breast Cancer Patients: Monitoring of Elimination of Disseminated Cytokeratin-positive Tumor Cells in Bone Marrow”, Clinical Canser Research vol. 5, 3999-4004.
Cha et al. (1996) “Random phage mimotopes recognized by monoclonal antibodies against the pyruvate dehydrogenase complex-X2 (PDC-E2)”, Proc. Natl. Acad. Sci. USA, vol. 93, pp. 10949-10954 Immunology.
D'Mello et al. (1997) “Definition of the Primary Structure of Hepatitis B Virus (HBV) pre-S Hepatocyte Binding Domain Using Random Peptide Libraries”, VIROLOGY vol. 237, pp. 319-326.
Huang et al. (1999) “Epidermal Growth Factor Receptor Blockade with C225 Modulates Proliferation, Apoptosis, and Radiosensitivity in Squamous Cell Carcinomas of the Head and Neck”, Cancer Research vol. 59, pp. 1935-1940.
Martin, et al. (1999) “Expression of the 17-1A antigen in gastric and gastro-oesophageal junction adenocarcinomas: a potential immunotherapeutic target?” J. Clin. Pathol, vol. 52, pp. 701-704.
McCormick et al. (1999) “Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv Epitopes in tobacco plants”, Proc. Natl. Acad. Sci. USA vol. 96, pp. 703-708 Medical Sciences.
Milpied, et al. (2000) “Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients”, Annals of Oncology II Suppl.S113-S116 Kluwer Academic Publishers.
Orlandi et al. (1994) “Antigenic and Immunogenic mimicry of the HER2
eu oncoprotein by phage-displayed peptides”, Eur. J. Immunol. vol. 24, pp. 2868-2873.
Poczatek et al. (1999) “Ep-Cam Levels in Prostatic Adenocarcinoma and Prostatic Intraepithelial Neoplasia”, The Journal of Urology, vol. 162, pp. 1462-1466.
Punt (1998) “New Drugs in the Treatment of Colorectal Carcinoma”, CANCER, vol. 83, No. 4, pp. 679-689.
Turpen et al. (1995) “Malaria Epitopes Expressed on the Surface of Recombinant Tobacco Mosaic Virus”, Bio/Technology vol. 13, pp. 53-57.
Zwick, et al. (1998) “Phage-displayed peptide libraries”, Current Opinion in Biotechnology, vol. 9: pp. 427-436.
Mittelman, Abraham et al., “Human high molecular weight melanoma-associated antigen (HMV-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: Induction of humoral anti-HMV-MAA immunity and prolongation of survival in patients with stage IV melanoma,” Proc. Natl. Acad. Sci. USA, vol. 89, pp. 446-470, Jan. 1992.
Mittelman, A. et al., “Active Specific Immunotherapy in Patients with Melanoma. A Clinical Trial with Mouse Antiidiotypic Monoclonal Antibodies Elicited with Syngeneic Anti-High-Molecular-Weight-Melanoma-Associated Antigen Monoclonal Antibodies,” J. Clin. Invest. Dec. 1990, 86, 2136-2144.
Geiser, Martin et al., “Identification of the Human Melanoma-associated Chondroitin Sulfate Proteoglycan Antigen Epitope Recognized by the Antitumor Monoclonal Antibody 763.74 from a Peptide Phage Library,” Cancer Research 59, 905-910, Feb. 15, 1999.
Mittelman, Abraham et al., “Human High Molecular Weight-Melanoma Associated Antigen Mimicry by Mouse Anti-Idiotypic Monoclonal Antibody MK2-23: Modulation of the Immunogenicity in Patients with Malignant Melanoma,” Clinical Cancer Research vol. 1, 705-173, Jul. 1995.
Ziai, M. Reza et al., “Analysis with Monoclonal Antibodies of the Molecular and Cellular Heterogeneity of Human High Molecular Weight Melanoma Associated Antigen,” Cancer Research 47, 2474-2480, May 1, 1987.
Price, Michael et al., “Enhancement of Cell-mediated Immunity in Melanoma Patients Immunized with Murine Anti-Idiotypic Monoclonal Antibodies (MELIMMUNE) That Mimic the High Molecular Weight Proteoglycan Antigen,” Clinical Cancer Research vol. 4, 2363-2370 Oct. 1998.
Ferrone, S. et al., “Active Specific Immunotherapy of Malignant Melanoma and Peptide Mimics of the Human High-Molecular-Weight Melanoma-Associated Antigen,” Recent Results Cancer Res., 2001. 158, 231-5).
Wison, Barry S. et al., Distribution and Molecular Characterization of a Cell-Surface and a Cytoplasmic Antigen Detectable in Huma
Breiteneder Heimo
Jensen-Jarolim Erika
Pehamberger Hubert
Scheiner Otto
Zielinski Christoph
Basi Nirmal Singh
Milbank Tweed Hadley & McCloy LLP
Saoud Christine J.
LandOfFree
Vaccine against cancer diseases that are associated with the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccine against cancer diseases that are associated with the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine against cancer diseases that are associated with the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3973818